Wajdi Kfoury, MD
Infectious Disease · Corbin, KYNPI 1124010814
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $51,425 of the $59,210 with a category attached, or 86.9%. AbbVie accounts for 95.0% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $18,049 and has fallen 91.2% since, to $1,592 in 2025. Among infectious disease clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 284 payments — averaging $208.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$56K
- Shionogi Inc$540
- Paratek Pharmaceuticals, Inc.$397
- Merck$394
- Melinta Therapeutics, LLC$381
- Aimmune Therapeutics, Inc.$225
- plus $1K from 15 others
What the payments were for
- Speaking & faculty fees$51,42587%
- Travel & lodging$2,4904%
- Food & beverage$5,2589%
- Education$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 137 | $56,256 |
| Shionogi Inc | 23 | $540 |
| Paratek Pharmaceuticals, Inc. | 21 | $397 |
| Merck | 22 | $394 |
| Melinta Therapeutics, LLC | 19 | $381 |
| Aimmune Therapeutics, Inc. | 12 | $225 |
| Insmed, Inc. | 11 | $216 |
| Gilead | 12 | $182 |
| Novo Nordisk | 7 | $134 |
| Astellas Pharma US Inc | 4 | $124 |
| Xeris Pharmaceuticals, Inc. | 4 | $58 |
| Novartis | 1 | $56 |
| Sunovion Pharmaceuticals Inc. | 1 | $45 |
| Cequr Corporation | 1 | $41 |
| Dynavax Technologies Corporation | 2 | $40 |
| Bayer | 2 | $35 |
| Sanofi-aventis U.S. LLC | 1 | $26 |
| Lilly USA, LLC | 1 | $18 |
| BETA Bionics, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$59,210 in reported general payments places this provider in the 90th percentile of 100 infectious disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 12 | $34,595 |
| Cefepime Hcl | 34 | $15,259 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 40 | $8,467 |
| CeftriaxoneCeftriaxone Sodium | 14 | $3,482 |
| Methenamine Hippurate | 29 | $1,406 |
| Cefazolin Sodium | 19 | $1,019 |
| Rifampin | 22 | $596 |
| Ethambutol Hcl | 15 | $484 |
| Fluconazole | 18 | $468 |
| Cefdinir | 29 | $437 |
| Azithromycin | 24 | $415 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $370 |
| Doxycycline Hyclate | 30 | $368 |
| Amoxicillin | 14 | $221 |
| Cephalexin | 18 | $220 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Corbin
- Fadi Al AkhrassPikeville$311K
- Julio RamirezLouisville$256K
- Martin GnoniLouisville$194K
- Paul SchulzLouisville$189K
- David DoughertyLexington$145K
- Tariq MehmoodLouisville$75K
- Charles RoseLexington$68K
- Marty AllenLexington$40K
- Daniel RodrigueLexington$37K
- John MeekLexington$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.